Holen Sie sich die Stockscreener-App
4.12
1.20%
-0.05
Handel nachbörslich:
4.16
0.04
+0.97%
Schlusskurs vom Vortag:
$4.17
Offen:
$4.24
24-Stunden-Volumen:
4.77M
Relative Volume:
2.07
Marktkapitalisierung:
$362.04M
Einnahmen:
$30.91M
Nettoeinkommen (Verlust:
$-209.47M
KGV:
-1.238
EPS:
-3.3279
Netto-Cashflow:
$-147.13M
1W Leistung:
+4.57%
1M Leistung:
-3.29%
6M Leistung:
-46.84%
1J Leistung:
-20.62%
1-Tages-Spanne:
$4.11
$4.425
1-Wochen-Bereich:
$3.85
$4.425
52-Wochen-Spanne:
$3.55
$11.24
Verastem Inc Stock (VSTM) Company Profile
Firmenname
Verastem Inc
Sektor
Branche
Telefon
(781) 292-4200
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
4.12 | 362.04M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2026-02-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-16 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-04-10 | Eingeleitet | Jefferies | Buy |
| 2025-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-31 | Bestätigt | BTIG Research | Buy |
| 2024-09-30 | Eingeleitet | Guggenheim | Buy |
| 2023-11-21 | Fortgesetzt | BTIG Research | Buy |
| 2023-09-27 | Eingeleitet | B. Riley Securities | Buy |
| 2023-06-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-07 | Fortgesetzt | Alliance Global Partners | Buy |
| 2022-04-29 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-03-09 | Eingeleitet | Truist | Buy |
| 2021-07-01 | Eingeleitet | Alliance Global Partners | Buy |
| 2021-05-24 | Hochstufung | BTIG Research | Neutral → Buy |
| 2019-06-20 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Eingeleitet | BTIG Research | Buy |
| 2018-05-02 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-03-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-03-24 | Bestätigt | H.C. Wainwright | Buy |
| 2015-09-29 | Herabstufung | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Herabstufung | Jefferies | Buy → Hold |
| 2015-09-29 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Herabstufung | Mizuho | Buy → Neutral |
| 2015-09-28 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
| 2015-05-12 | Bestätigt | UBS | Buy |
| 2015-04-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-01-23 | Bestätigt | ROTH Capital | Buy |
| 2014-07-08 | Fortgesetzt | Oppenheimer | Perform |
| 2014-02-11 | Eingeleitet | Mizuho | Buy |
Alle ansehen
Verastem Inc Aktie (VSTM) Neueste Nachrichten
Verastem And The Biotech Side Of Penny Stocks - Kalkine Media
Verastem stock holds Outperform at Mizuho on pancreatic trial data - Investing.com
Verastem Inc (VSTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Verastem Inc (VSTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Verastem Inc (VSTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Verastem Inc (VSTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Verastem (VSTM) Reveals Promising Results in Pancreatic Cancer S - GuruFocus
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Verastem: 'Buy' Positive RAMP-205 Data And Extensive VS-7375 Registration Program (VSTM) - Seeking Alpha
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer - Benzinga
Verastem Oncology reports positive RAMP 205 data in front-line pancreatic cancer - grafa.com
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Verastem (Nasdaq: VSTM) reports RAMP 205 pancreatic data and starts KRAS G12D trial - Stock Titan
Pancreatic cancer trial shows 86% six-month survival on Verastem drug combo - Stock Titan
Verastem Inc (VSTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Verastem (VSTM) Begins Patient Dosing in Crucial Cancer Trial - GuruFocus
Verastem Inc (VSTM) Institutional Confidence - TradingKey
Verastem Inc (VSTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Verastem Inc (VSTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Verastem doses first Patient in TARGET-D 201 Phase 2 trial of VS-7375 - TipRanks
Verastem, Inc. initiates first dosing in Phase 2 trial for KRAS G12D pancreatic cancer therapy - Traders Union
Verastem Oncology announced that its oral inhibitor VS-7375, targeting Kras G12d-mutated metastatic pancreatic cancer, has completed dosing for the first patient in the Target-D 201 phase II registration-directed study. - Bitget
Verastem doses first patient in pancreatic cancer trial By Investing.com - Investing.com Nigeria
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer - Business Wire
First patient receives KRAS G12D pill for metastatic pancreatic cancer - Stock Titan
Verastem, Inc. plans conference to unveil progress on KRAS G12D trial - Traders Union
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program - Business Wire
Verastem, Inc. Stock Plummets to New 52-Week Low of $3.56 - MarketsMojo
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Jazz Pharmaceuticals (JAZZ) and Humana (HUM) - The Globe and Mail
VSTM Technical Analysis & Stock Price Forecast - Intellectia AI
Verastem’s VS-7375 receives FDA fast track status for lung cancer - Investing.com UK
Verastem announces FDA Fast Track designation for VS-7375 - TipRanks
Verastem Inc. (VSTM) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Ongoing Clinical ProgressEPS Surprise History - newsline.com
Verastem, Inc. receives U.S. FDA fast track for KRAS G12D inhibitor in NSCLC treatment - Traders Union
Verastem (VSTM) Surges 11% Following FDA Fast Track Designation - GuruFocus
Verastem’s VS-7375 receives FDA fast track status for lung cancer By Investing.com - Investing.com South Africa
Verastem (VSTM) Receives Fast Track Designation for Cancer Treat - GuruFocus
Verastem stock rises on FDA fast track for lung cancer drug - Investing.com Canada
Verastem Initiates Phase 2 Target-D 202 Trial For Advanced NSCLC - TradingView
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung - Business Wire
Verastem Inc stock (US92335V1008): Nasdaq-listed oncology player steadies around late-May levels - AD HOC NEWS
VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Verastem (VSTM) Declines 2.5% as Biotech Sector Headwinds PersistPullback Trade - thelegaladvocate.com
Verastem (NASDAQ: VSTM) director receives 108,000 restricted stock units - Stock Titan
New Verastem (NASDAQ: VSTM) director files initial Form 3 ownership - Stock Titan
[144] Verastem, Inc. SEC Filing - Stock Titan
Biopharma Verastem Oncology joins Jefferies healthcare fireside chat June 3 - Stock Titan
Verastem Oncology to Present at Jefferies Healthcare Conference - marketscreener.com
Verastem: Robert Gagnon Stepped Down From Board Following End of Term on May 21 >VSTM - Moomoo
Director at Verastem (VSTM) receives 36,000 RSUs as equity award - Stock Titan
Finanzdaten der Verastem Inc-Aktie (VSTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):